Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer

Prior treatment

• Sample providers criteria
  • Male and female patients aged less than 19 years
  • Patients with histologically not confirmed gastric adenocarcinoma
  • Patients with histologically confirmed stage Ⅰ or Ⅳ
  • Patients who have not undergone radical gastrectomy
  • Patients who have received neoadjuvant chemotherapy or radiotherapy
  • Patients with distant or peritoneal metastasis at the time of surgery or residual tumors after surgery
  • Patients who have not signed the study's written consent and human derived research agreement (Form 34)

Other

• Sample criteria
  • The FFPE tumor specimens in storage have a tumor amount of less than 20% and therefore cannot be tested
  • The quantity and quality of RNA are not sufficient for analysis

• Sample providers criteria
  • Male and female adult patients aged 19 years or over
  • Patients with histologically confirmed gastric adenocarcinoma
  • Patients with histologically confirmed stage Ⅱ or Ⅲ
  • Patients who have undergone radical gastrectomy
  • Patients who have not received neoadjuvant chemotherapy and radiotherapy
  • Patients who have undergone a radical gastrectomy and who show no evidence of residual tumors as observed with the unaided eye or through a microscope
  • Patients who have signed a written consent of the study and signed a human derived research agreement (Form 34)
• Sample criteria
  • The formalin-fixed paraffin-embedded (FFPE) tumor specimens in storage have a tumor amount of at least 20% and therefore can be tested.
  • The quantity (not less than 400ng) and quality (A260/280 of not less than 1.8) of RNA are sufficient for analysis.